Biohaven Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BHVN New York 2830 www.biohaven.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biohaven Ltd.

Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation - Jun 1st, 2026 5:30 am
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile - May 26th, 2026 5:30 am
Biohaven (BHVN) Is Up 9.1% After Narrower Q1 Loss And New Mixed Shelf Registration - What's Changed - May 6th, 2026 5:15 pm
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why - May 5th, 2026 10:00 am
A Look At Biohaven (BHVN) Valuation After Narrower Q1 Loss And New Pivotal Trial And Funding Plans - May 4th, 2026 10:35 pm
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results - May 4th, 2026 2:02 pm
KCNQ2 Developmental and Epileptic Encephalopathy Market Research Report 2025-2035, Competitive Analysis of Biohaven, Xenon Pharma, Lundbeck, Praxis Precision Medicines, NeuShen Therapeutics - Apr 28th, 2026 2:06 am
Moderate Buy Rating Seen For Biohaven Ltd. (BHVN) - Apr 22nd, 2026 8:18 am
Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating - Apr 19th, 2026 6:11 pm
Why Biohaven Stock Crushed it on Monday - Apr 13th, 2026 4:01 pm
Here is why Biohaven (BHVN) is Among the Top Healthcare Stocks Insiders Are Buying - Apr 12th, 2026 3:18 pm
Biohaven (BHVN) Fuels Confidence With Encouraging Azetukalner Data - Apr 1st, 2026 3:35 am
Can Biohaven (BHVN) Redefine Obesity Treatment By Targeting Lean Mass Preservation With Taldefgrobep? - Mar 29th, 2026 7:07 pm
Biohaven (BHVN) Completes Enrollment in Phase 2 Obesity Study of Taldefgrobep Alfa - Mar 27th, 2026 1:29 am
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - Mar 23rd, 2026 11:37 am
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash - Mar 21st, 2026 6:09 pm
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment - Mar 19th, 2026 5:30 am
uniQure stock surges 36% on FDA official’s departure - Mar 9th, 2026 6:23 am
Biohaven Reshapes Pipeline And Funding As Late Stage Trials Approach - Mar 4th, 2026 12:08 am
SSR Mining Stock Up 180% as New $5 Million Stake Signals Gold Conviction - Mar 3rd, 2026 2:10 pm